Martínez-Sánchez LM, Pamplona-Sierra AP, Aranzazú-Ceballos AD, Velásquez-Cano JP, Arboleda-Rojas M, Arango-Giraldo S

Language: Spanish
References: 17
Page: 186-190
PDF size: 192.96 Kb.

ABSTRACT

Background. Acute lymphoblastic leukemia (ALL) is a hemato-oncologic pathology that develops in the bone marrow and affects the lymphoid lineage including B, T and natural killer cells. This disease occurs mainly in children and is characterized by specific cytogenetic abnormalities of differentiation and proliferation of lymphoid precursor cells.
Materials and methods. Retrospective, cross-sectional, descriptive study conducted from 2014 to 2019, which included pediatric patients with a diagnosis of acute lymphoblastic leukemia and bacterial blood isolation. For the analysis of qualitative variables, relative and absolute frequencies were used, while quantitative variables were analyzed using median, median, and standard deviation, interquartile ranges according to their distribution.
Results. Twenty-eight children with a diagnosis of all and infection were included, with a median age of 4.5 years (min 1-max 10), with 50% (14) for both male and female gender. The 85.7% were from the urban area and 100% were affiliated to the General System of Social Security in Health (SGSSS). The type of chemotherapy was differentiated in 89.3% (25), where the curative stage was the most present in the study in 78.6% (22/25). In addition, 50% (14) were in the induction phase of chemotherapy, 35.7% (10) in consolidation, and 10.7% (3) in maintenance. According to the type of infectious agent, 90.3% (28) were of bacterial origin and 9.7% (3) were of fungal origin, Escherichia coli being the most prevalent. Regarding antimicrobial treatment 96.4% (27) received some antibacterial agent and 3.6% (1) received antifungal.
Conclusions. This study highlights the high frequency of infections in pediatric patients with all, especially of bacterial origin, where this is associated with immunosuppression that is generated by chemotherapy.

REFERENCES

1. Yadav, V., Ganesan, P., Veeramani, R. y Kumar, V.D.m“Philadelphia-like acute lymphoblastic leukemia: a systematicreview”, Clin Lymphoma Myeloma Leuk, 2021, 21 (1): e57-e65. doi: 10.1016/j.clml.2020.08.011.

2. García Rico, O.L., Sánchez Medina, J.G., Sánchez Becerra,E., Cepeda Brav, J.A., Tejeda Nava, F.J., Rocha Viggiano,A.K. et al., “Impacto de la leucemia linfoblásticaaguda en el microbioma y lesiones bucales: revisión dealcance”, Rev Cient Odontol (Lima), 2023, 10 (4): e131.doi: 10.21142/2523-2754-1004-2022-131.

3. Zhang, Y., Zhang, G., Wang, Y., Ye, L., Peng, L., Shi, R.et al., “Current treatment strategies targeting histonedeacetylase inhibitors in acute lymphocytic leukemia:a systematic review”, Front Oncol, 2024, 14: 1324859.doi: 10.3389/fonc.2024.1324859.

4. Zhai, Y., Hong, J., Wang, J., Jiang, Y., Wu, W., Lv, Y.,Guo, J. et al., “Comparison of blinatumomab and cart-cell therapy in relapsed/refractory acute lymphoblasticleukemia: a systematic review and meta-analysis”,Expert Rev Hematol, 2024, 17 (1-3): 67-76. doi:10.1080/17474086.2023.2298732.

5. Nabizadeh, F., Momtaz, S., Ghanbari-Movahed, M.,Qalekhani, F., Mohsenpour, H., Aneva, I.Y. et al., “Pediatricacute lymphoblastic leukemia management usingmultitargeting bioactive natural compounds: a systematicand critical review”, Pharmacol Res, 2022, 177:106116. doi: 10.1016/j.phrs.2022.106116.

6. Aamir, S., Anwar, M.Y., Khalid, F., Khan, S.I., Ali, M.A. yKhattak, Z.E., “Systematic review and meta-analysis ofcd19-specific car-t cell therapy in relapsed/refractoryacute lymphoblastic leukemia in the pediatric and youngadult population: safety and efficacy outcomes”, ClinLymphoma Myeloma Leuk, 2021, 21 (4): e334-e347. doi:10.1016/j.clml.2020.12.010.

7. Jain, S. y Kapoor, G., “Invasive aspergillosis in childrenwith acute leukemia at a resource-limited oncology center”,J Pediatr Hematol Oncol, 2015, 37 (1): e1-e5. doi:10.1097/mph.0000000000000159.

8. Yeh, T.C., Liu, H.C., Hou, J.Y., Chen, K.H., Huang, T.H. etal., “Severe infections in children with acute leukemiaundergoing intensive chemotherapy can successfullybe prevented by ciprofloxacin, voriconazole, or micafunginprophylaxis”, Cancer, 2014, 120 (8): 1255-1262. doi:10.1002/cncr.28524.

9. Zeng, X.L., Heneghan, M.B. y Badawy, S.M., “Adherenceto oral chemotherapy in acute lymphoblastic leukemiaduring maintenance therapy in children, adolescents,and young adults: a systematic review”, Curr Oncol,2023, 30 (1): 720-748. doi: 10.3390/curroncol30010056.

10. Fardell, J.E., Vetsch, J., Trahair, T., Mateos, M.K., Grootenhuis,M.A., Touyz, L.M. et al., “Health-related qualityof life of children on treatment for acute lymphoblasticleukemia: a systematic review”, Pediatr Blood Cancer,2021, 64 (9). doi: 10.1002/pbc.26489.

11. Zajac-Spychala, O., Kampmeier, S., Lehrnbecher, T.y Groll, A.H., “Infectious complications in paediatrichaematopoetic cell transplantation for acute lymphoblasticleukemia: current status”, Front Pediatr, 2022, 9:782530. doi: 10.3389/fped.2021.782530.

12. Ministerio de Salud y Protección Social, “Aseguramientoal Sistema General de Salud”, Ministerio de Saludy Protección Social de Colombia. Consultado el 27de noviembre de 2024. Disponible en: https: //www.minsalud.gov.co/protecc/Regimensubsidiado/Paginas/asegura-al -sistema--general - salud.asp.

13. Yin, T., Han, J., Hao, J., Yu, H., Qiu, Y., Xu, J. et al., “Clinicalcharacteristics and risk factors of acute lymphoblasticleukemia in children with severe infection duringmaintenance treatment”, Cancer Med, 2023, 12 (19):19372-19382. doi: 10.1002/cam4.6495.

14. Jain, S. y Kapoor, G., “Invasive aspergillosis in childrenwith acute leukemia at a resource-limited oncology center”,Journal of Pediatric Hematology/Oncology, 2015,37 (1), e1-e5. doi: 10.1097/mph.0000000000000159.

15. Yeh, T.C., Liu, H.C., Hou, J.Y., Chen, K.H., Huang, T.H.,Chang, C.Y. et al., “Severe infections in children withacute leukemia undergoing intensive chemotherapycan successfully be prevented by ciprofloxacin, voriconazole,or micafungin prophylaxis”, Cancer, 2014, 120(8): 1255-1262. doi: 10.1002/cncr.28524.

16. Fuentes, L. et al., “Características de la leucemia linfoblásticaaguda y neutropenia febril en niños y adolescentesatendidos en un hospital de Guayaquil, Ecuador”, RevPerú Med Exp Salud Pública, 2018, 35: 272-278.

17. Atienza, A. y Lassaletta, A., “Leucemias. Leucemia linfoblásticaaguda”, Pediatría Integral, 2016, 20 (6): 380-389.